Post-marketing surveillance of Cosentyx (secukinumab) for hidradenitis suppurativa, pediatric plaque psoriasis, and juvenile idiopathic arthritis in Korea

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, single-arm, prospective observational post-marketing surveillance of patients in Korea treated with Cosentyx within approved indications. Treatment decisions are made by the treating physician as part of routine care and no additional diagnostics or monitoring beyond standard practice are required. The study enrolls adults (≥18) with moderate-to-severe hidradenitis suppurativa and children aged 6–18 with moderate-to-severe plaque psoriasis or enthesitis-related/juvenile psoriatic arthritis receiving Cosentyx. Data on safety, tolerability, and routine clinical outcomes will be collected during standard clinic visits.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Hidradenitis suppurativa:

1. Adults 18 years of age and older with moderate to severe hidradenitis suppurativa who are or will be receiving Cosentyx within the scope of approved indication.
2. Patients who have agreed to participate in study (written informed consent)

Pediatric plaque psoriasis:

1. Patients with moderate to severe plaque psoriasis between the ages of 6 and 18 years who are receiving or will receive Cosentyx within the scope of approved indication.
2. Patients with patient or guardian consent to participate in study (written informed consent)

Juvenile idiopathic arthritis:

1. Enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category patients with enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category between the ages of 6 and 18 years and are receiving or will receive Cosentyx within the scope of approved indication.
2. Patients with patient or guardian consent to participate in study (written informed consent)

Exclusion Criteria:

1. Patients who are contraindicated according to national prescribing information
2. Patients participating in other interventional clinical trials

Where it's running

• Novartis Investigative Site
  Seoul, Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Novartis Pharmaceuticals
• Email: novartis.email@novartis.com
• Phone: +41613241111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term real-world tracking of secukinumab treatment for moderate to severe hidradenitis suppurativa in Italy

  This project will see how secukinumab works and is used in adults with moderate to severe hidradenitis suppurativa in Italy.

  Recruiting at 16 sites Novartis · Ancona, AN and 15 other locations · NCT07543419

• Secukinumab outcomes in Canadians with hidradenitis suppurativa

  It will see how well secukinumab works and how safe it is for adults in Canada with moderate-to-severe hidradenitis suppurativa who were newly prescribed it in routine care.

  Recruiting at 15 sites Novartis · Calgary, Alberta and 14 other locations · NCT07282015

• Using infrared cameras to help detect juvenile arthritis in kids

  This study tests whether infrared thermography can help identify joint inflammation in children with juvenile idiopathic arthritis compared with standard tests.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens · NCT07914179

• BTK inhibitor remibrutinib in hidradenitis suppurativa shows how it works in adults

  This phase 1 trial tests whether remibrutinib can safely affect HS in adults with moderate to severe disease.

  Recruiting at 2 sites Phase 1 Novartis · San Diego, California and 1 other locations · NCT07855276

• Olatorepatide vs placebo for adults with moderate-to-severe hidradenitis suppurativa who are overweight

  This study tests whether olatorepatide can help people with hidradenitis suppurativa who are overweight or obese.

  Recruiting Phase 2 Regeneron Pharmaceuticals · The Bronx, New York · NCT07830329

• Oral health, saliva bacteria, and disease activity in children with JIA

  This study checks if how active juvenile idiopathic arthritis is relates to oral health in children who already receive rheumatology care.

  Recruiting Shanghai Jiao Tong University School of Medicine · Shanghai, Pudongxinqu · NCT07799831

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.